2 Pharma Stocks You Can Buy and Hold for the Next Decade fool.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fool.com Daily Mail and Mail on Sunday newspapers.
AstraZeneca chiude il primo semestre con un aumento dei ricavi del 23% a 15,5 miliardi di dollari e
un +31% nel solo secondo trimestre. E' quanto si legge in una nota del gruppo. Dai vaccini anti
Covid son giunti ricavi per 894 milioni (1. (ANSA)
Biopharma M&A set for a strong H2 despite political noise—and Biogen and Gilead look like buyers: analysts fiercepharma.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercepharma.com Daily Mail and Mail on Sunday newspapers.
At the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
This article is for information purposes only. The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice. It is important to perform your own research before making any investment and take independent advice from a registered investment advisor.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to accuracy, completeness, or the suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. The author will not be held responsible for information that is found at the end of links posted on this
Regional Segment Analysis
The report focuses on detailed analysis of major regions like North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, Columbia), and Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa).
Target Audience for this Report
– Rare Hematology Treatment manufacturers
– Rare Hematology Treatment industry associations
– Product managers, Rare Hematology Treatment industry administrator, C-level executives of the industries
– Market Research and consulting firms
– Research & Clinical Laboratories
Potential opportunities and challenges analysis in Rare Hematology Treatment market.
Current and future market outlook in the developed and emerging regional markets.